slightli consensu expect street
drift lower approach prgo guidanc one
major shortfal fine-tun due higher
expect tax rate follow passag tax reform
item state tax reform like neg impact
tax rate basi point us may strike
conserv tone highlight previou statement
regard year number past confer call remind
investor analyst updat forecast accord
firstcal brokerag estim updat sinc
novemb prior new tax guidanc addit new
ceo start quarter would surpris compani
take even conserv approach guidanc order
allow new ceo fulli get arm around busi
reiter market perform rate revis price target
opinion excel recoveri year
manag execut restructur plan appear
start healthier busi year
ago exampl consum hc america grew last
two quarter follow consecut quarter declin
perrigo launch nexium also provid
boost
model line guidanc expect chc
america grow us over-the-counter healthcar market
current grow adjust oper margin
guidanc segment chc
expect constant currenc basi
exclud divest busi chci grow in-lin slightli
faster european over-the-counter healthcar market
estim current grow announc
increment invest chci
absorb expect oper margin expans
approxim bp per year reach high-teen year
line model rx guidanc assum
growth constant currenc basi driven new launch off-set
high singl digit price eros tax expect
adjust effect tax rate increas bp
maintain market perform rate lower price
target result updat dcf
base year adjust revenu spend estim
updat expect tax rate reflect guidanc overal
like progress made believ larg
reflect share base current estim
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap adjust ep exclud one-tim item
compani prioriti stock list
compani data secur llc estim reuter
factset secur llc estim
factset secur llc estim
factset secur llc estim
new old hc hc incom adjust ebitda expens expens incom per perrigo compani plc
price target
price target base dcf valuat includ discount rate termin
multipl integr larg part outlook carri substanti risk
risk includ turnaround brand consum healthcar busi weak rx
believ share perform market evid emerg recent
turnaround durabl particularli relat eu busi gener busi
recent under-perform
began packag gener home remedi year later one top
over-the-count over-the-counter consum good product compani market share privat label
store brand also among lead compani pharmaceut gener market
well activ pharmaceut ingredi api market
